By Chris Wack Clearmind Medicine shares were down 45% to $1.62 after the company entered into definitive agreements with institutional investors for the.
By Dean Seal Shares of Clearmind Medicine soared after the psychedelic-medicine biotechnology company said a trial of its treatment for cocaine addiction has.
By Colin Kellaher Clearmind Medicine shares lost more than half of their value and hit an all-time low on Thursday after the biotech company said it was.
By Sabela Ojea Shares of Clearmind Medicine climbed Wednesday after the company said it has signed its first human clinical trial agreement with Johns.